FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     RYAN ARTHUR F						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]								5. Relationship of Rep (Check all applicable) X Director Officer (give t			ting Person(s) to Issuer  10% Owner  Other (specif		vner	
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023									below			other (s	ыреспу 	
(Street) TARRYTOWN NY 10591					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Application)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					on	
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
4 Title of 6	Popurity (Inc			n-Deriva 2. Transactio		Secui 2A. Dee		s Ac	quire	d, Di	isposed o	•		ially			6 000	orobin	7. Nature	
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day					Execution Date,			Transaction Code (Instr. 8)		4. Securities Acquire Disposed Of (D) (Ins				5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		of Indirect Beneficial Ownership		
								Ì	Code	v	Amount	(A) or (D)	Price			ed ction(s) 3 and 4)			(Instr. 4)	
Common	05/01/2023					<b>S</b> <sup>(1)</sup>		16	D	\$802.6	67 <sup>(2)</sup> 19,03		9,031	1	D					
Common Stock				05/01/2023				<b>S</b> <sup>(1)</sup>		30	D	\$803.5	58 <sup>(3)</sup> 19,001		9,001	D				
Common Stock				05/01/2023				<b>S</b> <sup>(1)</sup>		2	D	\$804.5	51 <sup>(4)</sup> 18,999		8,999	D				
Common Stock				05/01/2023					<b>S</b> <sup>(1)</sup>		5	D	\$805.3	34(5)	18,994		]	D		
Common Stock				05/01/2023					<b>S</b> <sup>(1)</sup>		15	D	\$806.5	806.53(6)		18,979		D		
Common Stock 05				05/01/202	23			<b>S</b> <sup>(1)</sup>		17	D	\$807.	<b>5</b> <sup>(7)</sup>	18,962		D				
Common Stock 05/01/202						23		<b>S</b> <sup>(1)</sup>			15	D	\$808.1	11(8)	18,947		]	D		
		Tal	ole II -								posed of, convertib				Owne	t				
1. Title of Derivative Security (Instr. 3)	I. Title of Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) If any			emed 4. ion Date, Trans Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		umber vative urities uired or oosed O) tr. 3, 4	6. Date Exe Expiration (Month/Day		rcisable and Date	7. Titl Amou Secur Under	e and int of rities rlying ative rity (Instr.	8. P Der Sec	rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	/ Oi Fo Oi (I)	o. wnership orm: irect (D) r Indirect (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares							
Explanatio	n of Respons	ses:																		

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022.
- 2. Represents volume-weighted average price of sales of 16 shares of Company stock on May 1, 2023 at prices ranging from \$802.57 to \$802.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price
- 3. Represents volume-weighted average price of sales of 30 shares of Company stock on May 1, 2023 at prices ranging from \$803.22 to \$803.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price
- 4. Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2023 at prices ranging from \$804.20 to \$804.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price.
- 5. Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2023 at prices ranging from \$805.22 to \$805.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price.
- 6. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2023 at prices ranging from \$806.01 to \$806.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price.
- 7. Represents volume-weighted average price of sales of 17 shares of Company stock on May 1, 2023 at prices ranging from \$807.12 to \$807.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price
- 8. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2023 at prices ranging from \$808.00 to \$808.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2023 at each separate price

/s/\*\*Arthur F. Ryan

05/03/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.